{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Samples&page=16",
    "query": {
      "intervention": "Biological Samples",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 541,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Samples&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Samples&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T15:54:30.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04857697",
      "title": "Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Breast Adenocarcinoma",
        "Stage I Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Probiotic",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-07-01",
      "completion_date": "2023-03-08",
      "has_results": false,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857697"
    },
    {
      "nct_id": "NCT06058377",
      "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "HER2-Negative Breast Carcinoma",
        "Hormone Receptor-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Genetic Testing",
          "type": "OTHER"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3680,
      "start_date": "2023-11-27",
      "completion_date": "2032-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 561,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 431 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06058377"
    },
    {
      "nct_id": "NCT02997228",
      "title": "Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colorectal Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2018-01-19",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 445,
      "location_summary": "Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more",
      "locations": [
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02997228"
    },
    {
      "nct_id": "NCT01203033",
      "title": "Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 68,
      "start_date": "2010-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01203033"
    },
    {
      "nct_id": "NCT07578116",
      "title": "Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic HER2-Positive Breast Carcinoma",
        "Oligometastatic Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Breast Conservation Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclin-Dependent Kinase 4 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Cyclin-Dependent Kinase 6 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "HER2-targeted Therapy",
          "type": "DRUG"
        },
        {
          "name": "Hormone Therapy",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Boost",
          "type": "RADIATION"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Taxane Compound",
          "type": "DRUG"
        },
        {
          "name": "Total Mastectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ultrasound Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 562,
      "start_date": "2027-03-09",
      "completion_date": "2033-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 59,
      "location_summary": "Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Greenwich",
          "state": "Connecticut"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07578116"
    },
    {
      "nct_id": "NCT06224673",
      "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Low Breast Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography (CT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Amiloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Laura Huppert, MD, BA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-06-05",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06224673"
    },
    {
      "nct_id": "NCT02163473",
      "title": "Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "Septic patients",
          "type": "PROCEDURE"
        },
        {
          "name": "Healthy Control",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 63,
      "start_date": "2013-01",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-13",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163473"
    },
    {
      "nct_id": "NCT05755269",
      "title": "Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Atypical Ductal Hyperplasia",
        "Breast Atypical Lobular Hyperplasia",
        "Breast Carcinoma",
        "Breast Lobular Carcinoma In Situ"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Genotyping",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 75 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2023-03-14",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755269"
    },
    {
      "nct_id": "NCT03250832",
      "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "TSR-033",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2017-08-08",
      "completion_date": "2023-02-13",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03250832"
    },
    {
      "nct_id": "NCT05807126",
      "title": "Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Castration-Resistant Prostate Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Magrolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-05",
      "completion_date": "2026-12-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-11-03T15:54:30.407Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Orange, California • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05807126"
    }
  ]
}